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1. Introduction
  Nasopharyngeal carcinoma (NPC) is one of the most 
common head and neck carcinomas in Southern China, 
special in Guangdong, Hainan, Guangxi, Hunan and Fujian 
provinces[1]. Genetic factors and environmental factors 
including Epstein- Barr virus are the two important risk 
factors for NPC. Although the advanced equipments and 
technologies in radiotherapy and chemotherapy have been 
greatly applied in recent years, the 5-year survival rate of 
patients suffered with NPC remains no more than 70%. 
  Provirus integration site for Moloney murine leukemia 
virus 1 (Pim-1) is one of the Serine/threonine kinases, which 
is firstly reported in hematological malignancies[2]. Due to 
the ability of co-operation with c-Myc and Gfi1, Pim-1 is 
also deemed as a proto-oncogene and crucial player in the 
process of malignant transformation[3,4], however, its role in 
nasopharyngeal carcinoma remains unclear. 
  In this investigation, we examined the expression level of 
Pim-1 and studied its roles in various differentiated cell 
lines of NPC. Our results showed that the up-regulation 
of Pim-1 was associated with the differentiation type 
of NPC and administration of Pim-1 special inhibitor, 
quercetagetin, effectively suppressed NPC cells proliferation 
and migration. Our results indicate that over-expression of 
Pim-1 contributes to NPC progression, and targeting Pim-1 
may be a potential interest strategy in NPC treatments.
Objective: To explore the role of proto-oncogene Pim-1 in the proliferation and migration 
of nasopharyngeal carcinoma (NPC) cells. Methods: Pim-1 expressions in NPC cell lines 
CNE1, CNE1-GL, CNE-2Z and C666-1 were examined by RT-PCR, western blotting and 
immunoflucesence, respectively. After CNE1, CNE1-GL and C666-1 cells were treated with 
different concentrations of Pim-1 special inhibitor, quercetagetin, the cell viability, colony 
formation rate and migration ability were analyzed. Results: Pim-1 expression was negative 
in well-differentiated CNE1 cells, whereas expressed weakly positive in poor-differentiated 
CNE-2Z cells and strongly positive in undifferentiated C666-1 cells. Interestingly, CNE1-GL 
cells that derived from CNE1 transfected with an Epstein Barr virus latent membrane protein-1 
over-expression plasmid displayed stronger expression of Pim-1. Treatment of CNE1-GL and 
C666-1 cells with quercetagetin significantly decreased the cell viability, colony formation rate 
and migration ability but not the CNE1 cells. Conclusions: These findings suggest that Pim-1 
overexpression contributes to NPC proliferation and migration, and targeting Pim-1 may be a 
potential treatment for anti-Pim-1-expressed NPCs.
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2. Materials and methods
2.1. Cell culture
  NPC cell lines CNE1 (well-differentiated, obtained from 
Institute of Virology, Chinese Academy of Preventive 
Medicine), CNE-2Z (poor-differentiated, established in 
our lab in 1980s) and C666-1 (undifferentiated, obtained 
from Sun Yat-Sen University Cancer Center) were grown in 
Dulbecco’s modified Eagle’s medium (DMEM, Hyclone, China) 
supplemented with 10% fetal bovine serum (FBS, Hyclone, 
China) and 100 U/mL penicillin and 0.1 mg/mL streptomycin. 
NPC cell line CNE1-GL was derived from CNE1 cells 
transfected with EBV LMP-1 eukaryotic expression plasmid 
PAT-GFP-LMP1, which was established previously in our 
lab, was maintained in DMEM contained with 10% FBS,
0.5 毺g/mL puromycin (Sigmal-Aldrich, Shanghai, China), 
100 U/mL penicillin and 0.1 mg/mL streptomycin. All cells 
were maintained at 37 曟 in a 5% CO2 atmosphere.
2.2. Drug treatment and cell viability
  Inhibitor of Pim-1, quercetagetin (Cal Chemical Corp, 
Coventry, RI, USA), was dissolved in dimethyl sulfoxide 
(DMSO), and the final concentration of DMSO in completed 
medium was 0.3% (v/v). CNE1, CNE1-GL, CNE-2Z and 
C666-1 cells (2×103/well) were placed in 96-well plates. Cells 
were cultured in DMEM supplemented with quercetagetin 
(0, 0.55, 5.5, 11 毺M) or DMSO (0.3%, v/v) for 48 hours. After 
twice washed with PBS, total 100 毺L DMEM plus 10 毺L 
Cell Counting Kit-8 (CCK-8) reagents (Biyuntian, Jiangsu, 
China) were added per wells for additional 2 hours, and then 
the optical density (OD) was measured using a microplate 
reader (Multiskan MKS, Thermo Scientific, Waltham, MA, 
USA) by dual wavelength mode (450/630 nm). Each group 
was duplicated six times and experiment was repeated three 
times.
2.3. Colony formation assay
  CNE1, CNE1-GL and C666-1 cells treated with or without 
Pim-1 special inhibitor quercetagetin (5.5 毺M) were seeded 
in 6-well plates (500 cells/well) and maintained in complete 
medium for up to two weeks. The cell colonies were then 
visualized by Giemsa staining.
2.4. RNA extraction and RT-PCR
  Total RNA was extracted with TaKaRa RNAiso plus reagent 
(TakaRa Biotechnology (Dalian) Co., Ltd.). The procedure 
of RT-PCR was performed according to the instruction of 
PrimeScript® One Step RT-PCR Kit Ver.2 (TakaRa). 1毺g of 
total RNA was used as a template and cDNAs was amplified 
by Mastercycler® Gradient Thermal cycler (Eppendorf, 
Germany) at the annealing tempreture of 60 ℃ with total 
29 cycles. The pairs of primers synthesized by Sangon 
Biotech Co., Ltd.(Shanghai, China) as follows were used: 
Pim-1 forward: 5’-GCT ACG ATG GGA CCC GAG TGT-
3’,Pim-1 reverse: 5’-GAG TAT CTA TGG GAG GAG TTG 
AGG C-3’, yielding a 575 bp product; 毬-actin forward: 5’-
CGT GGA CAT CCG CAA AGA C-3’, 毬-actin reverse: 5’-
AAG AAA GGG TGT AAC GCA ACT-3’, yielding a 306 bp 
product. Products of PCR were separated by 1.5% agarose 
gel electrophoresis and visualized under UV using InGenius 
LHR gel Documentation and analysis system (InGene). The 
transcription levels of 毬-actin served as a loading control.
2.5. Western blotting
  Western blot t ing  was per formed as  descr ibed 
previously[5-7]. Protein homogenates were separated by 
SDS–PAGE using gel electrophoresis and transferred to 
a nitrocellulose membrane (BioRad, Hercules, CA, USA). 
Membranes were incubated with primary antibody against 
Pim-1 (1:300, sc-7859, Santa Cruz Biotechnology, Santa Cruz, 
CA, USA), p-BAD (Ser112) (1:1 000, Cell Signaling, MA, USA) 
and BAD (1:1 000, Cell Signaling, MA, USA) in TBST plus 5% 
skimmed milk overnight at 4 ℃. Membranes were washed 
and incubated with HRP-conjugated secondary antibodies 
for 1 hour at room temperature. Bands were visualized using 
enhanced chemiluminescent reagents (Thermo Fisher, 
Rockford, IL, USA) and analyzed using an InGenius LHR gel 
Documentation and analysis system (InGene, Fredrick, MO, 
USA).
2.6. Immunofluorescent staining
  Indirect immunofluorescence was performed on NPC cells 
grown on glass coverlips as described previously[8]. After 
incubation overnight with the primary antibodies (Pim-1, 
1:100) at 4 ℃, the antigenic sites were localized using RITC-
conjugated rabbit anti-goat IgG (1:100, Protein Tech Group, 
Inc, Chicago, IL, USA). Images of the antigenic sites were 
captured by a laser scanning confocal microscope (TCS 
SP5Ⅱ; Leica, Germany).
2.7. Transwell migration assay
  Transwell migration assay was performed as described 
previously[5,9]. Briefly, 8-毺m pore size polycarbonate 
membranes (BD Biosciences, NJ, USA) were coated with 
Matrigel (100 毺g/cm
2; BD Biosciences) and incubated 
overnight. CNE1, CNE1-GL and C666-1 cells were treated 
with quercetagetin (0, 5.5 毺M) or DMSO (0.3%, v/v) for 48 
hours, then 2×105 cells in DMEM supplemented with 1% 
BSA together with quercetagetin (0, 5.5 毺M) or DMSO (0.3%, 
v/v) were placed in upper chamber. The bottom chamber 
consisted of medium DMEM with 10% FBS was used as 
a chemoattractant. Cells were incubated for additional
6 hours, after which the inserted membranes were fixed for 
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20 minutes in 4% paraformaldehyde in PBS and stained with 
Eosin staining. Then membranes were washed with PBS 
and cut from the inserts. Cells on the upper surface of the 
membrane were scraped with cotton swab and membranes 
were mounted with glycerol. Invaded cells on the lower 
surfaces of the membranes were counted within ten 
representative fields in triplicate inserts.
2.8. Statistical analysis
  The statistical analysis was carried out by using PRISM 
Software (GraphPad Software, CA, USA). The data were 
expressed as Mean±SD. For analysis of differences between 
two groups, Student’s t-test was performed. For multiple 
groups, ANOVA was carried out followed by Student-
Newman-Keuls test. The level of statistical significance was 
set at P< 0.05.
3. Results
3.1. Expression profile of Pim-1 in NPC cell lines
  To examine the expression profile of Pim-1 in different NPC 
cell lines, CNE1, CNE1-GL, CNE-2Z and C666-1 cells were 
used in the present study. As shown in Figure 1, a variable 
expression of Pim-1 was observed both at mRNA and protein 
levels in NPC cell lines. In general, a negative expression 
of Pim-1 was detected in well-differentiated CNE1 cells, 
while an increased expression of Pim-1 was observed in 
CNE-2Z cells (poor-differentiated NPC) and C666-1 cells 
(undifferentiated NPC). To our interest, the CNE1-GL cells 
that transfected with an EBV-LMP1 over-expression plasmid 
displayed the stronger Pim-1 expression, and C666-1 cells 
that EBV stably harbored while LMP-1 expressed very low 
levels[10], also displayed a moderate Pim-1 expression. 
Finally, results of immunofluorescent staining showed that 
Pim-1 was located in cytoplasm and nuclear in different 
NPC cell lines (Figure 2), which was similar to the expression 
profile of Pim-1 in some solid tumors[11-13].
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Figure 1. Pim-1 expression in different NPC cell lines. 
CNE1, CNE1-GL, CNE2Z and C666-1 cells were seeded in 24-
well plates, 3 wells for each cell lines (n = 3) were harvested for the 
analysis of Pim-1 Expression by RT-PCR (a) and western blotting 
analysis (b). * P< 0.05 vs. CNE1, # P<0.05 vs. CNE1-GL. 
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Figure 2. Expression and cellular location of Pim-1 in NPC cell lines 
examined by immunoflurecence. 
NPC cells were grown on glass coverlips, after incubated the coverlips 
with primary antibody overnight, the antigenic sites of Pim-1 were 
located by TRITC-conjugated rabbit-anti goat IgGs and observed by 
confocal microscope. Scale bar = 50 毺M.
 
3.2. Administration of quercetagetin attenuates NPC 
proliferation
  We further examined the effects of targeting Pim-1 on 
changes of cell phenotypes. Pim-1 kinase has showed 
a promotion to cells proliferation. Thus, we examined 
the role of Pim-1 in NPC cells proliferation. As shown 
by Figure 3, administration of quercetagetin, a selected 
Pim-1 inhibitor[14,15], lead to decrease of cell viability 
(Figure 3a) and colony formation ability (Figure 3b) in the 
Pim-1-expressed CNE1-GL and C666-1 cells but not the 
Pim-1 negative CNE1 cells, suggesting Pim-1 expression 
contributes to NPC cells proliferation. 
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Figure 3. Effects of administration of quercetagetin on NPC cells 
proliferation. 
After the CNE1-GL, C666-1 and CNE1 were treated with different 
concentrations of Qucetergatin or DMSO (0.3%,v/v), the cell viability 
(a), colony formation rates (b) were assessed, respectively. * P<0.05 
vs. DMSO or control group (Quercetagetin 0 毺M), # P<0.05 vs. DMSO 
or control group (Quercetagetin 0 毺M).
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3.3. Effect of quercetagetin on NPC migration 
  The results of transwell assay showed that when 
quercetagetin was added, a decreased number of 
invaded NPC cells passed through the 8-毺M pore sized 
polycarbonate membrane were observed in CNE1-GL and 
C666-1 cells (Figure 4), indicating inhibition of Pim-1 
activity repressed NPC cells migration.
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Figure 4. Effects of administration of quercetagetin on NPC cells 
migration. 
After the CNE1-GL, C666-1 and CNE1 were treated with 
quercetagetinn (0, 5.5 毺M) or DMSO (0.3%, v/v), the migratory 
ability was assessed. Invaded cells on the lower surfaces of the 
membranes were counted within ten representative fields in triplicate 
inserts. * P<0.05 vs. DMSO or control group (Quercetagetin 0 毺M), 
# P<0.05 vs. DMSO or control group (Quercetagetin 0 毺M). Original 
magnification: ×100.  
 
3.4. Quercetagetin decreases Pim-1 activity in NPC cells
Administration of quercetagetin showed no significant 
influence on Pim-1 expression (Figure 5a), thus, the Pim-1 
activity was further assessed. Pim-1 kinase promotes 
inactivation of the BAD protein by phosphorylating it on 
the Ser112[16,17], thus, the modulation of the level of p-BAD 
at Ser112 implies the change of Pim-1 kinase activity. 
As shown in Figure 5b, treatment with quercetagetin 
significantly attenuated the levels of endogenous p-BAD 
(Ser112) in CNE1-GL cells but not in CNE1 cells, indicating 
administration of quercetagetin decreases Pim-1 activity in 
Pim-1-expressed NPC cells. 
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Figure 5. Effects of quercetagetin on Pim-1 expression and activity. 
a Pim-1 expression at transcription and translation levels was 
assessed by RT-PCR and western blotting in CNE1-GL and C666-1 
cells. b Changes of p-BAD (Ser112) and BAD were examined by 
western blotting in CNE1-GL and CNE1 cells.
4. Discussion
  The present study firstly analyzed Pim-1 expression 
in different types of NPC cell lines. Generally, well-
differentiated NPC cells CNE1 displayed a negative Pim-1 
expression, however, poor-differentiated CNE2Z and 
undifferentiated C666-1 cells exhibited a much stronger 
Pim-1 expression. These results indicated that Pim-1 may 
be closely related to the NPC progression. The results of 
this studies also demonstrated that the expression of Pim-1 
play a pivotal role in the proliferation and migration of NPC 
cells; when administration of quercetagetin, a selected 
Pim-1 activity inhibitor[14], significantly attenuated NPC 
proliferation and migration, suggesting that targeting Pim-1 
was a potential promising therapeutic approach for NPC. 
  Pim-1 contributes to the cell proliferation due to the cell 
cycle progression and decrease of apoptosis[18]. Morishita 
et al founded that Pim-1 kinases were phosphorylated 
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and then down-regulated p27Kip1 at the transcriptional 
and posttranscriptional levels[19]. Cdc25A/C, a direct 
transcriptional target for c-Myc, was physically interacted 
with and phosphorylated by Pim-1[20]. Besides, Pim-1 
promoted complex formation between NuMA, HP1beta, 
dynein and dynactin, a complex that is necessary for mitosis. 
p100, a transcriptional co-activator that interacts with the 
c-Myb transcription factor, was bind and phosphorylated 
by Pim-1, too[21]. BAD is a proapoptotic member of the 
Bcl-2 family that promotes cell death by displacing Bax 
from binding to Bcl-2 and Bcl-xL. Phosphorylation of BAD 
at Ser112 and Ser136 promotes binding of BAD to 14-3-3 
proteins to prevent an association between BAD with Bcl-2 
and Bcl-xl[22]. It has been shown that Pim-1 may play a 
pivotal role in the regulation of the survival signaling via 
modulation of Bcl-2 family member like BAD[16,17,23]. Pim-1 
kinase inactivates the BAD protein by phosphorylating it on 
the Ser112[16,17], thus, the modulation of the level of p-BAD 
at Ser112 implies the change of Pim-1 kinase activity. 
In the present study, administration of Pim-1 inhibitor, 
quercetagetin, showed no any significant impacts on Pim-1 
expression; however, a decreased p-BAD (Ser112) levels were 
revealed in Pim-1-expressed CNE1-GL and C666-1 cells, 
suggesting administration of quercetagetin represses Pim-1 
activity in NPC cells. In turn, a decrease of colony formation 
rate and cell viability was observed. Our results consisted 
with others reports in that treatment with Pim-1 inhibitors 
effectively induced a cell cycle arrest[24-27], and administration 
of Pim-1 siRNA inhibited cell proliferation[11,28-30]. 
  It is well known that there is a close relationship between 
NPC and EBV infection, especially the poor- and un-
differentiated NPC histological types. Latent membrane 
protein-1 (LMP-1) is EBV-encoded oncoprotein that 
could promote NPC to progress via activation of multiple 
signaling[31,32]. Recently, Kim et al reported that LMP-1 
could increase chemo-resistance via cytoplasmic 
sequestration of Pim-1 in MCF7 and Jurkat cells[33], 
suggesting that LMP-1-induced Pim-1 expression in 
lymphomas. In the present study, the well-differentiated 
NPC cell line CNE1 showed no Pim-1 expression, however, 
the CNE1-GL that established from CNE1 transfected with 
a LMP-1 over-expression plasmid[34], displayed a very 
strong Pim-1 expression. However, the C666-1 cells that 
EBV consistently harbored demonstrated a very low level 
of LMP-1[10], at the same time, showed a moderate Pim-1 
expression. The results of immunofluorescence revealed 
that Pim-1 located both in the nuclear and cytoplasm of 
NPC cells, however, an increase of Pim-1 expression in 
nuclear of CNE1-GL than C666-1 cells was evidenced by 
western blotting analysis (data not shown). These results 
indicated that LMP-1 could induce Pim-1 expression and 
may shift its cellular location. Based on the above results, 
it may be achieved that EBV infection could induced 
Pim-1 expression in NPC cells at least partially via LMP-
1-activiated singling. Further studies on the underlying 
mechanisms of EBV-induced Pim-1 expression and shift of 
cellular location are under investigation.
  To the best of our knowledge, it is the first report regarding 
the relationship between Pim-1 and NPCs. In the present 
study, we found that over-expression of Pim-1 was 
associated with NPC cells proliferation and migration; 
moreover, administration of Pim-1 special inhibitor, 
quercetagetin, effectively attenuated Pim-1 activity in 
NPC cells, which lead to a decreased cell proliferation 
and migration. In sum, our study provides evidences that 
targeting Pim-1 would be a potential promising approach in 
Pim-1-expressed NPCs.
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